WallStSmart

Fox Corp Class B (FOX)vsNovo Nordisk A/S (NVO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novo Nordisk A/S generates 1764% more annual revenue ($309.06B vs $16.58B). NVO leads profitability with a 33.1% profit margin vs 11.4%. NVO appears more attractively valued with a PEG of 4.88. NVO earns a higher WallStSmart Score of 55/100 (C).

FOX

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 7.0Value: 4.7Quality: 8.0
Piotroski: 5/9Altman Z: 2.44

NVO

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 10.0Value: 4.7Quality: 4.8
Piotroski: 3/9Altman Z: 2.08
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

FOXSignificantly Overvalued (-95.5%)

Margin of Safety

-95.5%

Fair Value

$28.36

Current Price

$52.35

$23.99 premium

UndervaluedFair: $28.36Overvalued
NVOSignificantly Overvalued (-59.4%)

Margin of Safety

-59.4%

Fair Value

$24.21

Current Price

$36.33

$12.12 premium

UndervaluedFair: $24.21Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FOX2 strengths · Avg: 8.0/10
P/E RatioValuation
12.6x8/10

Attractively priced relative to earnings

Price/BookValuation
2.0x8/10

Reasonable price relative to book value

NVO5 strengths · Avg: 9.8/10
P/E RatioValuation
10.4x10/10

Attractively priced relative to earnings

Return on EquityProfitability
60.7%10/10

Every $100 of equity generates 61 in profit

Profit MarginProfitability
33.1%10/10

Keeps 33 of every $100 in revenue as profit

Operating MarginProfitability
44.5%10/10

Strong operational efficiency at 44.5%

Market CapQuality
$165.02B9/10

Large-cap with strong market position

Areas to Watch

FOX4 concerns · Avg: 2.5/10
Revenue GrowthGrowth
2.0%4/10

2.0% revenue growth

PEG RatioValuation
11.992/10

Expensive relative to growth rate

EPS GrowthGrowth
-35.8%2/10

Earnings declined 35.8%

Free Cash FlowQuality
$-773.00M2/10

Negative free cash flow — burning cash

NVO4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
4.882/10

Expensive relative to growth rate

Revenue GrowthGrowth
-7.6%2/10

Revenue declined 7.6%

EPS GrowthGrowth
-4.7%2/10

Earnings declined 4.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : FOX

The strongest argument for FOX centers on P/E Ratio, Price/Book.

Bull Case : NVO

The strongest argument for NVO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 33.1% and operating margin at 44.5%.

Bear Case : FOX

The primary concerns for FOX are Revenue Growth, PEG Ratio, EPS Growth.

Bear Case : NVO

The primary concerns for NVO are Piotroski F-Score, PEG Ratio, Revenue Growth.

Key Dynamics to Monitor

FOX profiles as a value stock while NVO is a declining play — different risk/reward profiles.

FOX carries more volatility with a beta of 0.54 — expect wider price swings.

FOX is growing revenue faster at 2.0% — sustainability is the question.

FOX generates stronger free cash flow (-773M), providing more financial flexibility.

Bottom Line

NVO scores higher overall (55/100 vs 51/100), backed by strong 33.1% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Fox Corp Class B

COMMUNICATION SERVICES · ENTERTAINMENT · USA

Fox Corporation is an American mass media company headquartered in New York City.

Novo Nordisk A/S

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.

Want to dig deeper into these stocks?